Skip to main content
SpringerLink
Log in
Book cover

Hughes Syndrome pp 307–318Cite as

β2-glycoprotein I and Anti-β2-glycoprotein I Antibodies

  • Chapter

  • 733 Accesses

Conclusions

Because β2-GPI was found to be a major antigen for aPL, many studies have been focused on the physiological role of β2-GPI, on mechanism of thrombosis induced by anti-β2-GPI antibody, and on clinical significance of this autoantibody. Physiological roles of β2-GPI have been reported, although “true” property in human has yet to be determined. Several epitopes for anti-β2-GPI antibodies are known, however, all of the anti-β2-GPI antibodies may not be pathogenic and anti-β2-GPI antibodies are heterogeneous. What we learn from these clinical reports would be as follows. First, the standardization of the assay system for aPL is urgent. Second, measurement of aPL using multiple methods is favored in order to establish better assay for diagnosis and/or for prediction of disease activity. Last, more prospective, multi-center studies will be needed after standardization of the assay systems.

Recently, pathogenic roles of anti-β2-GPI antibodies have been reported in the fields of coagulation and fibrinolysis, atherosclerosis, or signal transduction and cell activation. These findings may contribute to better and specific therapies for patients with APS.

Keywords

  • Systemic Lupus Erythematosus
  • Lupus Anticoagulant
  • Anticardiolipin Antibody
  • Tropical Spastic Paraparesis
  • Negative Feedback Pathway

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (Canada)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (Canada)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990;336:177–178.

    CrossRef  PubMed  CAS  Google Scholar 

  2. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544–1547.

    CrossRef  PubMed  CAS  Google Scholar 

  3. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120–4124.

    CrossRef  PubMed  CAS  Google Scholar 

  4. Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1997;77:486–491.

    PubMed  CAS  Google Scholar 

  5. Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 1995;74:1120–1125.

    PubMed  CAS  Google Scholar 

  6. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000;43:1982–1993.

    CrossRef  PubMed  CAS  Google Scholar 

  7. Sugi T, McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 1995;86:3083–3089.

    PubMed  CAS  Google Scholar 

  8. Cugno M, Dominguez M, Cabibbe M, et al. Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome. Br J Haematol 2000;108:871–875.

    CrossRef  PubMed  CAS  Google Scholar 

  9. Bidot CJ, Jy W, Horstman LL, et al. Factor VII/VIIa: a new antigen in the anti-phospholipid antibody syndrome. Br J Haematol 2003;120:618–626.

    CrossRef  PubMed  CAS  Google Scholar 

  10. Jones DW, Mackie IJ, Gallimore MJ, Winter M. Antibodies to factor XII and recurrent fetal loss in patients with the anti-phospholipid syndrome. Br J Haematol 2001;113:550–552.

    CrossRef  PubMed  CAS  Google Scholar 

  11. Rampazzo P, Biasiolo A, Garin J, et al. Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins. Thromb Haemost 2001;85:57–62.

    PubMed  CAS  Google Scholar 

  12. Tsutsumi A, Matsuura E, Ichikawa K, et al. Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:1466–1474.

    PubMed  CAS  Google Scholar 

  13. Pierangeli SS, Liu SW, Anderson G, Barker JH, Harris EN. Thrombogenic properties of murine anti-cardiolipin antibodies induced by β2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation 1996;94:1746–1751.

    PubMed  CAS  Google Scholar 

  14. Bouma B, de Groot PG, van den Elsen JM, et al. Adhesion mechanism of human β2-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999;18:5166–5174.

    CrossRef  PubMed  CAS  Google Scholar 

  15. Schwarzenbacher R, Zeth K, Diederichs K, et al. Crystal structure of human ?2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999;18:6228–6239.

    CrossRef  PubMed  CAS  Google Scholar 

  16. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997;107:569–573.

    CrossRef  PubMed  CAS  Google Scholar 

  17. Kobayashi K, Kishi M, Atsumi T, et al. Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 2003;44:716–726.

    CrossRef  PubMed  CAS  Google Scholar 

  18. Pittoni V, Ravirajan CT, Donohoe S, Machin SJ, Lydyard PM, Isenberg DA. Human monoclonal anti-phospholipid antibodies selectively bind to membrane phospholipid and β2-glycoprotein I (β2-GPI) on apoptotic cells. Clin Exp Immunol 2000;119:533–543.

    CrossRef  PubMed  CAS  Google Scholar 

  19. Nimpf J, Bevers EM, Bomans PH, et al. Prothrombinase activity of human platelets is inhibited by β2-glycoprotein-I. Biochim Biophys Acta 1986;884:142–149.

    PubMed  CAS  Google Scholar 

  20. Schousboe I, Rasmussen MS. Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by β2-glycoprotein I and anti-β2-glycoprotein I. Thromb Haemost 1995;73:798–804.

    PubMed  CAS  Google Scholar 

  21. Nimpf J, Wurm H, Kostner GM. Interaction of β2-glycoprotein-I with human blood platelets: influence upon the ADP-induced aggregation. Thromb Haemost 1985;54:397–401.

    PubMed  CAS  Google Scholar 

  22. Ieko M, Tarumi T, Takeda M, Naito S, Nakabayashi T, Koike T. Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis. J Thromb Haemost 2004;2:612–618.

    CrossRef  PubMed  CAS  Google Scholar 

  23. Mori T, Takeya H, Nishioka J, Gabazza EC, Suzuki K. β2-glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost 1996;75:49–55.

    CrossRef  PubMed  CAS  Google Scholar 

  24. Sheng Y, Reddel SW, Herzog H, et al. Impaired thrombin generation in β2-glycoprotein I null mice. J Biol Chem 2001;276:13817–13821.

    PubMed  CAS  Google Scholar 

  25. Hoeg JM, Segal P, Gregg RE, et al. Characterization of plasma lipids and lipoproteins in patients with β2-glycoprotein I (apolipoprotein H) deficiency. Atherosclerosis 1985;55:25–34.

    CrossRef  PubMed  CAS  Google Scholar 

  26. Bancsi LF, van der Linden IK, Bertina RM. β2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992;67:649–653.

    PubMed  CAS  Google Scholar 

  27. Yasuda S, Tsutsumi A, Chiba H, et al. β2-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 2000;152:337–346.

    CrossRef  PubMed  CAS  Google Scholar 

  28. Takeuchi R, Atsumi T, Ieko M, et al. Coagulation and fibrinolytic activities in 2 siblings with β2-glycoprotein I deficiency. Blood 2000;96:1594–1595.

    PubMed  CAS  Google Scholar 

  29. Nakaya Y, Schaefer EJ, Brewer HB Jr. Activation of human post heparin lipoprotein lipase by apolipoprotein H (β2-glycoprotein I). Biochem Biophys Res Commun 1980;95:1168–1172.

    CrossRef  PubMed  CAS  Google Scholar 

  30. Wurm H. β2-Glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem 1984;16:511–515.

    CrossRef  PubMed  CAS  Google Scholar 

  31. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994;179:457–462.

    CrossRef  PubMed  CAS  Google Scholar 

  32. Subang R, Levine JS, Janoff AS, et al. Phospholipid-bound β2-glycoprotein I induces the production of anti-phospholipid antibodies. J Autoimmun 2000;15:21–32.

    CrossRef  PubMed  CAS  Google Scholar 

  33. Roubey RA, Eisenberg RA, Harper MF, Winfield JB. “Anticardiolipin” autoantibodies recognize β2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995;154:954–960.

    PubMed  CAS  Google Scholar 

  34. Sheng Y, Kandiah DA, Krilis SA. Anti-β2-glycoprotein I autoantibodies from patients with the “antiphospholipid” syndrome bind to β2-glycoprotein I with low affinity: dimerization of β2-glycoprotein I induces a significant increase in anti-β2-glycoprotein I antibody affinity. J Immunol 1998;161:2038–2043.

    PubMed  CAS  Google Scholar 

  35. Arvieux J, Regnault V, Hachulla E, Darnige L, Roussel B, Bensa JC. Heterogeneity and immunochemical properties of anti-β2-glycoprotein I autoantibodies. Thromb Haemost 1998;80:393–398.

    PubMed  CAS  Google Scholar 

  36. Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other “antiphospholipid” autoantibodies. Blood 1994;8:2854–2867.

    Google Scholar 

  37. Tincani A, Spatola L, Prati E, et al. The anti-β2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species’ evolution. J Immunol 1996;157:5732–5738.

    PubMed  CAS  Google Scholar 

  38. Ambrozic A, Avicin T, Ichikawa K, et al. Anti-β2-glycoprotein I antibodies in children with atopic dermatitis. Int Immunol 2002;14:823–830.

    CrossRef  PubMed  CAS  Google Scholar 

  39. Ichikawa K, Tsutsumi A, Atsumi T, et al. A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG β2-glycoprotein I-dependent anticardiolipin and anti-β2-glycoprotein I antibodies. Arthritis Rheum 1999;42:2461–2470.

    CrossRef  PubMed  CAS  Google Scholar 

  40. Ichikawa K, Khamashta MA, Koike T, Matsuura E, Hughes GR. β2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994;37:1453–1461.

    PubMed  CAS  Google Scholar 

  41. Iverson GM, Victoria EJ, Marquis DM. Anti-β2 glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 1998;95:15542–15546.

    CrossRef  PubMed  CAS  Google Scholar 

  42. Reddel SW, Wang YX, Sheng YH, Krilis SA. Epitope studies with anti-β2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun 2000;15:91–96.

    CrossRef  PubMed  CAS  Google Scholar 

  43. McNeeley PA, Dlott JS, Furie RA, et al. β2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of β2-glycoprotein I. Thromb Haemost 2001;86:590–595.

    PubMed  CAS  Google Scholar 

  44. Igarashi M, Matsuura E, Igarashi Y, et al. Human β2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. Blood 1996;87:3262–3270.

    PubMed  CAS  Google Scholar 

  45. George J, Gilburd B, Hojnik M, et al. Target recognition of β2-glycoprotein I (β2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of beta2GPI in antibody binding. J Immunol 1998;160:3917–3923.

    PubMed  CAS  Google Scholar 

  46. Koike T, Ichikawa K, Atsumi T, Kasahara H, Matsuura E. β2-glycoprotein I-anti-β2-glycoprotein I interaction. J Autoimmun 2000;15:97–100.

    CrossRef  PubMed  CAS  Google Scholar 

  47. Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci U S A 1999;96:5164–5168.

    CrossRef  PubMed  CAS  Google Scholar 

  48. Hunt JE, Simpson RJ, Krilis SA. Identification of a region of β2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci U S A 1993;90:2141–2145.

    CrossRef  PubMed  CAS  Google Scholar 

  49. Wang MX, Kandiah DA, Ichikawa K, et al. Epitope specificity of monoclonal anti-β2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. J Immunol 1995;155:1629–1636.

    PubMed  CAS  Google Scholar 

  50. Shoenfeld Y, Krause I, Kvapil F, et al. Prevalence and clinical correlations of antibodies against six β2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J Clin Immunol 2003;23:377–383.

    CrossRef  PubMed  CAS  Google Scholar 

  51. Guerin J, Feighery C, Sim RB, Jackson J. Antibodies to β2-glycoprotein I-a specific marker for the antiphospholipid syndrome. Clin Exp Immunol 1997;109:304–309.

    CrossRef  PubMed  CAS  Google Scholar 

  52. Martinuzzo ME, Forastiero RR, Carreras LO. Anti β2 glycoprotein I antibodies: detection and association with thrombosis. Br J Haematol 1995;89:397–402.

    PubMed  CAS  Google Scholar 

  53. McNally T, Purdy G, Mackie IJ, Machin SJ, Isenberg DA. The use of an anti-β2-glycoprotein-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Br J Haematol 1995;91:471–473.

    PubMed  CAS  Google Scholar 

  54. Balestrieri G, Tincani A, Spatola L, et al. Anti-β2-glycoprotein I antibodies: a marker of antiphospholipid syndrome? Lupus 1995;4:122–130.

    PubMed  CAS  Google Scholar 

  55. Cabral AR, Cabiedes J, Alarcon-Segovia D. Antibodies to phospholipid-free β2-glycoprotein-I in patients with primary antiphospholipid syndrome. J Rheumatol 1995;22:1894–1898.

    PubMed  CAS  Google Scholar 

  56. Forastiero RR, Martinuzzo ME, Kordich LC, Carreras LO. Reactivity to β2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb Haemost 1996;75:717–720.

    PubMed  CAS  Google Scholar 

  57. Roubey RA, Maldonado MA, Byrd SN. Comparison of an enzyme-linked immunosorbent assay for antibodies to β2-glycoprotein I and a conventional anticardiolipin immunoassay. Arthritis Rheum 1996;39:1606–1607.

    PubMed  CAS  Google Scholar 

  58. Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GR. Specificity of ELISA for antibody to β2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996;35:1239–1243.

    CrossRef  PubMed  CAS  Google Scholar 

  59. Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-β2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995;22:1899–1906.

    PubMed  CAS  Google Scholar 

  60. Sanmarco M, Soler C, Christides C, et al. Prevalence and clinical significance of IgG isotype anti-β2-glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. J Lab Clin Med 1997;129:499–506.

    CrossRef  PubMed  CAS  Google Scholar 

  61. Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, Koike T. IgA class anti-β2-glycoprotein I in patients with systemic lupus erythematosus. J Rheumatol 1998;25:74–78.

    PubMed  CAS  Google Scholar 

  62. Pasquier E, Amiral J, de Saint ML, Mottier D. A cross sectional study of antiphospholipid-protein antibodies in patients with venous thromboembolism. Thromb Haemost 2001;86:538–542.

    PubMed  CAS  Google Scholar 

  63. Fanopoulos D, Teodorescu MR, Varga J, Teodorescu M. High frequency of abnormal levels of IgA anti-β2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome. J Rheumatol 1998;25:675–680.

    PubMed  CAS  Google Scholar 

  64. Lee SS, Cho ML, Joo YS, et al. Isotypes of anti-β2-glycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus. J Rheumatol 2001;28:520–524.

    PubMed  CAS  Google Scholar 

  65. Wilson WA, Morgan OC, Barton EN, et al. IgA antiphospholipid antibodies in HTLV-1-associated tropical spastic paraparesis. Lupus 1995;4:138–141.

    PubMed  CAS  Google Scholar 

  66. Bertolaccini ML, Atsumi T, Escudero CA, Khamashta MA, Hughes GRV. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 2001;28:2637–2643.

    PubMed  CAS  Google Scholar 

  67. Sammaritano LR, Ng S, Sobel R, et al. Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum 1997;40:1998–2006.

    PubMed  CAS  Google Scholar 

  68. Amengual O, Atsumi T, Khamashta MA, Bertolaccini ML, Hughes GR. IgG2 restriction of anti-β2-glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome: comment on the article by Sammaritano et al. Arthritis Rheum 1998;41:1513–1515.

    CrossRef  PubMed  CAS  Google Scholar 

  69. Galli M, Luciani D, Bertolini G, Barbui T. Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:2717–2723.

    CrossRef  PubMed  CAS  Google Scholar 

  70. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827–1832.

    CrossRef  PubMed  CAS  Google Scholar 

  71. Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol 1986;41:8–15.

    CrossRef  PubMed  CAS  Google Scholar 

  72. Santiago M, Martinelli R, Ko A, et al. Anti-β2-glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and Kala-azar. Clin Exp Rheumatol 2001;19:425–430.

    PubMed  CAS  Google Scholar 

  73. Giordano P, Galli M, Del Vecchio GC, et al. Lupus anticoagulant, anticardiolipin antibodies and hepatitis C virus infection in thalassaemia. Br J Haematol 1998;102:903–906.

    CrossRef  PubMed  CAS  Google Scholar 

  74. Audrain MA, Colonna F, Morio F, Hamidou MA, Muller JY. Comparison of different kits in the detection of autoantibodies to cardiolipin and β2 glycoprotein 1. Rheumatology (Oxford) 2004;43:181–185.

    CrossRef  CAS  Google Scholar 

  75. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000;43:1982–1993.

    CrossRef  PubMed  CAS  Google Scholar 

  76. Lopez LR, Dier KJ, Lopez D, Merrill JT, Fink CA. Anti-β2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol 2004;121:142–149.

    CrossRef  PubMed  CAS  Google Scholar 

  77. Lopez D, Kobayashi K, Merrill JT, Matsuura E, Lopez LR. IgG autoantibodies against β2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome. Clin Dev Immunol 2003;10:203–211.

    CrossRef  PubMed  CAS  Google Scholar 

  78. Ulcova-Gallova Z, Bouse V, Krizanovska K, Balvin M, Rokyta Z, Netrvalova L. β2-glycoprotein I is a good indicator of certain adverse pregnancy conditions. Int J Fertil Womens Med 2001;46:304–308.

    PubMed  CAS  Google Scholar 

  79. Lee RM, Emlen W, Scott JR, Branch DW, Silver RM. Anti-β2-glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome. Am J Obstet Gynecol 1999;181:642–648.

    CrossRef  PubMed  CAS  Google Scholar 

  80. Falcon CR, Martinuzzo ME, Forastiero RR, Cerrato GS, Carreras LO. Pregnancy loss and autoantibodies against phospholipid-binding proteins. Obstet Gynecol 1997;89:975–980.

    CrossRef  PubMed  CAS  Google Scholar 

  81. Faden D, Tincani A, Tanzi P, et al. Anti-β2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-β2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. Eur J Obstet Gynecol Reprod Biol 1997;73:37–42.

    CrossRef  PubMed  CAS  Google Scholar 

  82. Gris JC, Quere I, Sanmarco M, et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstetricians and Haematologists Study — NOHA. Thromb Haemost 2000;84:228–236.

    PubMed  CAS  Google Scholar 

  83. Lynch A, Byers T, Emlen W, Rynes D, Shetterly SM, Hamman RF. Association of antibodies to β2-glycoprotein 1 with pregnancy loss and pregnancy-induced hypertension: a prospective study in low-risk pregnancy. Obstet Gynecol 1999;93:193–198.

    CrossRef  PubMed  CAS  Google Scholar 

  84. Lee RM, Brown MA, Branch DW, Ward K, Silver RM. Anticardiolipin and anti-β2-glycoprotein-I antibodies in preeclampsia. Obstet Gynecol 2003;102:294–300.

    CrossRef  PubMed  CAS  Google Scholar 

  85. Carmo-Pereira S, Bertolaccini ML, Escudero-Contreras A, Khamashta MA, Hughes GR. Value of IgA anticardiolipin and anti-β2-glycoprotein I antibody testing in patients with pregnancy morbidity. Ann Rheum Dis 2003;62:540–543.

    CrossRef  PubMed  CAS  Google Scholar 

  86. Yamada H, Tsutsumi A, Ichikawa K, Kato EH, Koike T, Fujimoto S. IgA-class anti-β2-glycoprotein I in women with unexplained recurrent spontaneous abortion. Arthritis Rheum 1999;42:2727–2728.

    CrossRef  PubMed  CAS  Google Scholar 

  87. Bruce IN, Clark-Soloninka CA, Spitzer KA, Gladman DD, Urowitz MB, Laskin CA. Prevalence of antibodies to β2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review. J Rheumatol 2000;27:2833–2837.

    PubMed  CAS  Google Scholar 

  88. Shi W, Chong BH, Hogg PJ, Chesterman CN. Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost 1993;70:342–345.

    PubMed  CAS  Google Scholar 

  89. Takeya H, Mori T, Gabazza EC, et al. Anti-β2-glycoprotein I (β2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the β2GPI binding to phospholipids. J Clin Invest 1997;99:2260–2268.

    CrossRef  PubMed  CAS  Google Scholar 

  90. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989;74:2426–2432.

    PubMed  CAS  Google Scholar 

  91. Ieko M, Ichikawa K, Triplett DA, et al. β2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum 1999;42:167–174.

    CrossRef  PubMed  CAS  Google Scholar 

  92. Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998;79:276–281.

    PubMed  CAS  Google Scholar 

  93. Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 1993;168(1 Pt 1):206–210.

    PubMed  CAS  Google Scholar 

  94. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994;153:1328–1332.

    PubMed  CAS  Google Scholar 

  95. Conti F, Sorice M, Circella A, et al. β2-glycoprotein I expression on monocytes is increased in antiphospholipid antibody syndrome and correlates with tissue factor expression. Clin Exp Immunol 2003;132:509–516.

    CrossRef  PubMed  CAS  Google Scholar 

  96. Lutters BC, Derksen RH, Tekelenburg WL, Lenting PJ, Arnout J, de Groot PG. Dimers of β2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2’. J Biol Chem 2003;278:33831–33838.

    CrossRef  PubMed  CAS  Google Scholar 

  97. Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003;101:3495–3500.

    CrossRef  PubMed  CAS  Google Scholar 

  98. Ohkura N, Hagihara Y, Yoshimura T, Goto Y, Kato H. Plasmin can reduce the function of human β2 glycoprotein I by cleaving domain V into a nicked form. Blood 1998;91:4173–4179.

    PubMed  CAS  Google Scholar 

  99. Matsuura E, Igarashi J, Kasahara H, et al. Proteolytic cleavage of β2-glycoprotein I: reduction of antigenicity and the structural relationship. Intern Immunol 2000;12:1183–1192.

    CrossRef  CAS  Google Scholar 

  100. Horbach DA, van Oort E, Lisman T, Meijers JC, Derksen RH, de Groot PG. β2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost 1999;81:87–95.

    PubMed  CAS  Google Scholar 

  101. Yasuda S, Atsumi T, Ieko M, et al. Nicked β2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood 2004;103:3766–3772.

    CrossRef  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan

    Shinsuke Yasuda MD, Tatsuya Atsumi MD, PhD & Takao Koike MD

Authors
  1. Shinsuke Yasuda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tatsuya Atsumi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takao Koike MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lupus Research Unit, St Thomas’ Hospital, London, UK

    M. A. Khamashta MD, FRCP, PhD (Deputy Head) (Deputy Head)

Rights and permissions

Reprints and Permissions

Copyright information

© 2006 Springer-Verlag London Limited

About this chapter

Cite this chapter

Yasuda, S., Atsumi, T., Koike, T. (2006). β2-glycoprotein I and Anti-β2-glycoprotein I Antibodies. In: Khamashta, M.A. (eds) Hughes Syndrome. Springer, London. https://doi.org/10.1007/1-84628-009-5_25

Download citation

  • DOI: https://doi.org/10.1007/1-84628-009-5_25

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-873-2

  • Online ISBN: 978-1-84628-009-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

search

Navigation